The average product development period for the novel therapeutics is about 10-15 years, so we are just in the cusp of witnessing more product approvals soon in India. We will see at least five new products on the shelves in the next two to three years’ time
product to be approved by a regulatory body, anywhere in the worldothers being Cartistem( Korea), Prochymal( Canada), Temcell( Japan).
With Stempeucel ® declared as new drug by the regulatory body for treating CLI- > Stempeucel ® injection will be covered under medical insurance. Also, the drug will be eligible for exports. We are looking for a strategic pharma partner in India to market the product for CLI treatment in 2017. Stempeutics uses a novel patented technology in the manufacture of Stempeucel ® that has many advantages over other stem cell based products.
Stempeutics has also published Phase 1 data in Journal of Translational Medicine, Phase 2 data in Stem Cell Translational Medicine and CLI potency paper in Stem Cell Research Therapy journal.
Please tell us about the latest activities in terms of new research and product development at Stempeutics?
Stempuetics is working on two more innovative products. The second innovative product being developed by is Stempeucare ® range of cosmetics. It is developed from adult stem cells derived Growth Factors / Cytokines cocktail for various derma applications including rejuvenation of aging skin, hair fall control and hair growth, under eye cream etc. First product which has gone to the market is an intensive firming skin care cosmetic product, branded as Cutisera™. Cutisera™ product has 5 distinct benefits i. e.( 1) reduction of lines and wrinkles( 2) lightning of dark spots( 3) evenness of skin tone( 4) improvement in skin firmness( 5) improvement in skin hydration. It has been launched in India through partnership with Cipla in January, 2016.
Other products in the pipe
BIOVOICENEWS. COM 43